Enzyme inhibition assay for pyruvate dehydrogenase complex: Clinical utility for the diagnosis of primary biliary cirrhosis

Table 1 Detection of enzymatic inhibitory antibody to PDC by enzyme inhibition assay in non-PBC s

First author	Year	Case studied	Antigen source	Serum amount (μL)	Serum dilution	Positivity rate (%)1
Teoh	1991	Normal subject, AIH, ALD, RA, SLE	Commercial PDC	1002	0.388888889	0 / 62 (<1.7)
Teoh	1994	Healthy subject, immunopathic diseases	Commercial PDC	1002	0.388888889	0 / 42 (<2.4)
Omagari	1996	Adult blood donors, healthy women	Commercial PDC	2	Undiluted	0 / 186 (<0.6)
Schmit	1999	Healthy controls, viral hepatitis, AIH	TRACE EMA kit	4	Undiluted	0 / 92 (<1.1)
Jois	2000	Normal subject, AIC, AIH, ALD, RA, SLE, etc.	Commercial PDC	2	Undilute	4 / 1055 ( 0.4)
Hazama	2000	Healthy subject, ALD, viral hepatitis, fatty liver	TRACE EMA kit	4	Undiluted	0 / 50 (<2.0)
Jensen	2000	AIH, abnormal LFT patients, Normal blood donors, etc.	TRACE EMA kit	4	Undiluted	0 / 250 (<0.4)
Masuda	2002	Healthy subject, ALD, viral hepatitis, fatty liver, etc.	TRACE EMA kit	4	Undiluted	0 / 130 (<0.8)
Hazama	2002	Healthy subject, ALD, viral hepatitis, fatty liver, etc.	TRACE EMA kit	4	Undiluted	0 / 97 (<1.1)

¹When the numerator is zero, the percentage is calculated as a nominal value of <1. ²100 μL of doubling dilutions of serum from 1:500 in phosphate-buffered saline solution. PDC, pyruvate dehydrogenase complex; PBC, primary biliary cirrhosis; AIH, autoimmune hepatitis; ALD, alcoholic liver disease; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; EMA kit,Enzymatic mitochondrial Antibody (M2) Assay kit; AIC, autoimmune cholangitis; LFT; liver function tests.